Compare Novo Nordisk A/S (NVO) vs Remitly Global Inc (RELY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Remitly Global Inc — how do they compare? Novo Nordisk A/S trades at $38.05 (market cap $165.31B), while Remitly Global Inc trades at $23.84 (market cap $4.98B). The key difference: Novo Nordisk A/S is far larger — about 33.2× Remitly Global Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Remitly Global Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Remitly Global Inc for 53 Days on average.
| NVO | RELY | |
|---|---|---|
Market Cap | $165.31B | $4.98B |
Volume | 11,432,838 | 3,501,150 |
Sector | Health | Technology |
52-Week High | $63.98 | $26.92 |
52-Week Low | $35.29 | $12.20 |
Typical Hold Time | 116 Days | 53 Days |
Enterprise Value | $179.56B | $4.34B |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat expectations, with Q2 2026 EPS of $0.96 surpassing the $0.82 estimate. The company maintains robust cash flow generation with $119.1B operating cash flow in 2025.
NVO presents compelling value with a 9.71 P/E ratio below industry averages and 59% analyst buy ratings. Upside potential exists to the $44.67 consensus target, though competition from Eli Lilly and FDA regulatory delays pose near-term risks. The obesity drug pipeline remains a key growth driver, supported by recent licensing deals totaling nearly $4B.
RELY trades at $22.93, down 1.16% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. Revenue has grown from $654M in 2022 to $1.64B in 2025, with net income turning positive at $67.93M. The company recently announced a partnership with Etsy and reported Q2 2026 revenue growth of 20% to $495M, with active customers surpassing 10 million.
The outlook is positive, supported by robust earnings beats, expanding margins, and a consensus analyst price target of $30.50 implying significant upside. Key risks include reliance on continued customer growth, competitive pressures in digital payments, and market volatility. Institutional ownership trends and insider sales warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
